BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) will host a conference call featuring Dr. Hagop Kantarjian, M.D. to provide an update of sapacitabine Phase II clinical plans in patients with elderly AML, review Phase I sapacitabine data reported at the meeting of the American Society of Hematology (ASH) on December 8, and comment on the current therapeutic landscape for patients with acute myeloid leukemia (AML).
